Bicara Therapeutics (NASDAQ:BCAX) CFO Sells $34,158.30 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 1,882 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $18.15, for a total transaction of $34,158.30. Following the completion of the sale, the chief financial officer directly owned 145,355 shares of the company’s stock, valued at $2,638,193.25. The trade was a 1.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Ivan Hyep also recently made the following trade(s):

• On Monday, November 24th, Ivan Hyep sold 17,795 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.55, for a total transaction of $330,097.25.
• On Friday, November 21st, Ivan Hyep sold 605 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.15, for a total value of $10,980.75.

Bicara Therapeutics Trading Down 1.1%

Shares of NASDAQ BCAX opened at $16.59 on Thursday. Bicara Therapeutics Inc. has a 12-month low of $7.80 and a 12-month high of $19.71. The stock’s fifty day simple moving average is $17.53 and its two-hundred day simple moving average is $14.83. The stock has a market capitalization of $908.80 million, a PE ratio of -7.41 and a beta of -0.79.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). On average, equities analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc lifted its position in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Bicara Therapeutics by 73.0% during the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after purchasing an additional 1,474 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Bicara Therapeutics in the fourth quarter valued at approximately $45,000. Finally, Larson Financial Group LLC increased its holdings in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after buying an additional 3,595 shares during the period.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Wedbush reiterated an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. HC Wainwright reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Finally, Wells Fargo & Company raised their price target on Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $28.00.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.